Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression

• Liang Zhang ,

  Contributed equally to this work with: Liang Zhang, Manoj Bhasin

  Affiliation Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Manoj Bhasin ,

  Contributed equally to this work with: Liang Zhang, Manoj Bhasin

  Affiliation Division of Interdisciplinary Medicine and Biotechnology, and Genomics and Proteomics Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Rachel Schor-Bardach,

  Affiliations Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

  ⨯
• Xiaoen Wang,

  Affiliation Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Michael P. Collins,

  Affiliation Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America

  ⨯
• David Panka,

  Affiliation Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Prabhakar Putheti,

  Affiliation Departments of Surgery and Medicine, The Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Sabina Signoretti,

  Affiliations Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• David C. Alsop,

  Affiliation Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Towia Libermann,

  Affiliation Division of Interdisciplinary Medicine and Biotechnology, and Genomics and Proteomics Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Michael B. Atkins,

  Affiliation Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• James W. Mier,

  Affiliation Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• S. Nahum Goldberg,

  Affiliations Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

  ⨯
• Rupal S. Bhatt

  * E-mail: rbhatt@bidmc.harvard.edu

  Affiliations Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, Kidney Cancer Program of the Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States of America

  ⨯